InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
InMed Pharmaceuticals已收到批准其美國專利申請 16/644,484 的通知，該專利名爲 “用於大麻素產品生物合成的大腸桿菌代謝工程”
InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
InMed Pharmaceuticals已收到批准其美國專利申請 16/644,484 的通知，該專利名爲 “用於大麻素產品生物合成的大腸桿菌代謝工程”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。